About the webinar:
Super immunodeficient mice such as the NOG-EXL and NSG-SGM3 combine severe immunodeficiency with transgenic expression of human myeloid-stimulatory cytokines. These mouse strains support an improved expansion of human myeloid cell populations following engraftment with human CD34+ hematopoietic stem cells (HSC). The application of these valuable humanized immune system (HIS) models can be complicated by adverse events that limit their use in long-term studies.
In this webinar, Dr. Elinor Willis will cover the characterization of myeloid cell hyperactivation syndrome in CD34+ HSC-humanized NSG-SGM3 and NOG-EXL mice, including significant new histopathology data in various tissues. Learn about important differences in overall survival and severity of myeloid cell hyperactivation syndrome between strains. These differences are relevant to selecting the most appropriate HIS model for longer-term studies.
Watch this webinar to:
- Review key host strains used to develop humanized immune system mouse models that support expansion of both human lymphoid and myeloid cells
- Get insight into the type of adverse outcomes that can develop in myeloid-supportive HIS mice, including mast cell hyperplasia and lethal macrophage activation syndrome
- Explore how myeloid cell hyperactivation syndrome presents in two different host strains following HSC engraftment
- Discover how myeloid cell hyperactivation syndrome affects different tissues, lifespan, and study windows in HIS mice
